Japanese companies launch skin care formulas
of new skin care formulas in the same week. Kanebo has developed a
vitamin-B skin whitening product, while Kao has unveiled a formula
that claims to tighten skin pores, writes Simon Pitman.
Leading cosmetics supplier Kanebo says that it latest skin whitening formula has been developed using specific blends of vitamin B. Known as B-Mixia, the formula consists of vitamins B2 and B6, together with nicotinic-acid amide.
Kanebo said that, when taken as an oral supplement, B-mixia can inhibit changes in skin pigmentation caused by exposure to ultraviolet radiation. Skin whitening solutions have proved particularly popular in Asian countries in recent years, where the desire to reduce the effects of sun exposure, particularly to the face, is highly coveted.
This has resulted in a plethora of skin whitening product being launched on the market, many of which are said to have dubious marketing claims. However, Kanebo says that its B-Mixia formula is up to 50 times more effective than taking vitamin C and E, and last longer than L-cysteine - all of which are commonly used in a host of formulas currently on the market.
The formula is also claimed to inhibit the secretion of adrenocorticotropic, a hormone that is related to melanin formation. Melanin contributes to the formation of darkening skin and moles.
Meanwhile, Kao, which is a global cosmetic and personal care player, has announced the development of Skin Force Activator, an ingredient that is said to tighten epidermial cells and helps normalise the epidermal structure.
The formula was developed following Kao research showing that pores on the cheek expand and stand out because irregularity of the epidermal layer - a condition that is usually exacerbated by the ageing process.
Kao said that its research into the formula has proven that it has a clear effect on smoothing out the epidermal layer, allowing for a smoother, tighter appearance to the skin.
According to the newsource JCNN, both companies are due to present the new formulations at the forthcoming 125th Annual Meeting of the Pharmaceutical Society, to be held at the Tokyo Big Sight on 30 March.
